Cardax

Cardax Announces Breakthrough Longevity Results with ZanthoSyn® in NIH-Funded Study: ir.cardaxpharma.com/press-releases…

Cardax Refocuses on ZanthoSyn® Consumer Health Business: ir.cardaxpharma.com/press-releases…

Cardax ($CDXI) Voluntarily Suspends SEC Reporting Obligations: ir.cardaxpharma.com/press-releases…

Cardax ($CDXI) Reports Q1 2021 Results ir.cardaxpharma.com/press-releases…

Cardax ($CDXI) Reports 2020 Results ir.cardaxpharma.com/press-releases…

US Capital Global Securities Launches $10MM Convertible Preferred Stock Offering for Cardax, Inc. Learn more: bit.ly/Cardax #Health #HealthTech #pharmaceuticals #biopharmaceutical #cardiovascular #inflammation #disease #business #funding #finance #investment #news

Cardax ($CDXI) Reports Q3 2020 Results: ir.cardaxpharma.com/press-releases…

Cardax ($CDXI) Reports Q2 2020 Results: ir.cardaxpharma.com/press-releases…

Cardax ($CDXI) Reports Q1 2020 Results: ir.cardaxpharma.com/press-releases…

Cardax ($CDXI) Reports 2019 Annual Results: ir.cardaxpharma.com/press-releases…

Coronavirus Disease 2019 (COVID-19) can induce an extreme immune response; this association between infection and progression of disease with inflammation suggests a strategy that would partner anti-infective agents, with anti-inflammatory agents: cardaxpharma.com/coronavirus/

Cardax ($CDXI) Releases White Paper on the Potential Role of Astaxanthin in the Treatment of Coronavirus Disease: ir.cardaxpharma.com/press-releases… #covid19 #coronavirus #astaxanthin

Cardax ($CDXI) Announces Reverse Stock Split of Common Stock: ir.cardaxpharma.com/press-releases…

Cardax ($CDXI) Reports Q3 2019 Results: ir.cardaxpharma.com/press-releases…

Cardax ($CDXI) Announces Interim Results from CHASE Clinical Trial; Interim Review Demonstrates Beneficial Changes in Key Markers of Cardiovascular Health: ir.cardaxpharma.com/press-releases…

Cardax ($CDXI) Reports Q2 2019 Results: ir.cardaxpharma.com/press-releases…

Cardax ($CDXI) Files Registration Statement for Proposed $15 Million Follow-On Offering: ir.cardaxpharma.com/press-releases…

Cardax Reports Q1 2019 Results with Continued Progress Across its ZanthoSyn® Consumer Health Business, CHASE Human Clinical Trial, and Rx Development Programs: ir.cardaxpharma.com/press-releases…

Cardax ($CDXI) Reports 2018 Results. Revenues from Cardax's ZanthoSyn® more than doubled; CHASE clinical trial initiated; pharmaceutical development plans for CDX-101 and CDX-301 are underway: ir.cardaxpharma.com/press-releases…

Cardax CEO David G. Watumull will present at #NobleConXV on Monday, January 28, 2019 at 11:30 AM ET: ir.cardaxpharma.com/press-releases… $CDXI